Eli Lilly and Company (LLY) vs Merck & Co., Inc. (MRK)
See how Eli Lilly and Company and Merck & Co., Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$1,280.79
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
View Full Page$152.23
NYSE
Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.
View Full PageKey Metrics Comparison
Eli Lilly and CompanyLLY
Market Cap$1.142T
Price$1,280.79
24h Change+4.49%
24h Volume$3.75M
Employees50,000
Shares Outstanding944,818,881
Merck & Co., Inc.MRK
Market Cap$375.578B
Price$152.23
24h Change+12.62%
24h Volume$29.34M
Employees73,000
Shares Outstanding2,469,879,206
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
LLY
75.2%MRK
24.8%Volume Share
Share of combined 24h volume
LLY
11.3%MRK
88.7%24h Performance
Price change over last 24 hours
LLY
4.49%MRK
12.62%Price Comparison
Eli Lilly and Company
Merck & Co., Inc.